Quarter 2026 Financial Results Show Growth in Oncology and Animal Health Sales
Audio narration · Coming soon
The company reported total worldwide sales of $18.1 billion for the quarter, reflecting a 5% growth overall and 4% growth excluding foreign exchange effects. Key products driving growth include KEYTRUDA/KEYTRUDA QLEX with $8.6 billion in sales and WINREVAIR with $694 million, marking a 93% increase. Additionally, the company presented pivotal Phase 3 oncology trial data at the ESMO Congress, highlighting advancements in its diverse pipeline.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by gnews